Sprectranetics (NASDAQ:SPNC) rose 10% and touched a 52-week high after the company said late Monday its trial using laser atherectomy to treat patients suffering from peripheral artery disease (PAD) had achieved statistical endpoints. Separately, Stifel Nicolas repeated its Buy recommendation on the stock and raised its price target to $30 from $24. Spectranetics, a maker…
InterMune (NASDAQ:ITMN) more than doubled Tuesday to its highest value since May 2011 after saying data from a phase 3 trial showed its Pirfenidone drug significantly reduced the progression of idiopathic pulmonary fibrosis. Near midday, ITMN had jumped 126.6% at $31.63 per share in recent trading. Earlier it hit $37.22. Also, significant treatment effects were…
Zulily (NASDAQ:ZU) needed to deliver upside to consensus projections in the fourth quarter, and the magnitude of the top- and bottom-line beat was more than adequate.. The doubling of the active customer base year-to-year is encouraging, and the leverage on marketing spending highlights that there is still significant untapped demand. Flow-through to profitability on higher…
Bravo Brio Restaurant (NASDAQ:BBRG) delivered 4Q13 operating earnings of $0.30 per share. Results were driven by same-store sales of (1.3%) at Bravo and (1.5%) at Brio. Total revenues decreased approximately (5.2%) y/y to $106.1 million, based partially on same-store sales of (1.3%) at Bravo and (1.5%) at Brio. The company opened 4 new Brio during…
Shares in Apollo Investment Corporation (NASDAQ:AINV) dropped more than 5% pre-market after the company said it has priced a public offering of 12.0 million shares. Underwriters have the option to buy an additional 1.8 million shares. The company didn’t give the price of the offer. XOMA Corp (NASDAQ:XOMA) is moving nearly 5% higher after the…
Analysts at JMP Securities have initiated coverage of mountain resort operator Intrawest Resorts Holdings Inc. (NYSE:SNOW) with a Market Perform rating. The price target has been set at $17 a share. In pre-market activity, SNOW shares are unchanged at $8.07, and move within a 52-week range of $10.80 – $14.67. Shares of Cara Therapeutics (NASDAQ:CARA)…
Tech Analysis & Market News